PIK3CA and cancer: A recent study using next-generation sequencing technology to test cancer-related genes has shown that several targeted mutations (KRAS, PIK3CA, IRS2, Sox2, and HRR genes) may potentially become effective targeted treatment sites for patients (Pei et al., 2021).